StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.96−0.05 (-1.25%)

Close on Nov 16, 2026Market cap $193.61MP/E –Yield –

Artiva Biotherapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Artiva Biotherapeutics's operating margin for the twelve months ending Dec 31, 2024 was -26805.6%. For fiscal 2024 it was -26805.6%, against -91.6% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2024Dec 31, 2024-26805.6%−26714.0
FY2023Dec 31, 2023-91.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2024Mar 31, 2024-5773.7%–
Q4 FY2023Dec 31, 2023-509.4%–
Q3 FY2023Sep 30, 202340.6%–
Q2 FY2023Jun 30, 2023-338.1%–

More Artiva Biotherapeutics figures

See a number that looks wrong?